Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This outstanding appointment leads me to believe we will have a partnership versus a buyout......
Pharmacyte is on top of its game now-her bio is even on the company's website.
Exciting times ahead..... next up the WEED etf????
I think you missed reason number 23. Leonard Makowka, M.D., Ph.D.
Buy, accumulate, hold and wait.
Thanks Brian....great summary.
LOL.
We should have a contest to see which is first; the IND submission or the ETF.........we still have a bright future though very frustrating.
I totally agree. Bought more today. The price is insanely low given the quality of doctors involved.
Not a fan of the CEO but you have to like the technology. We are getting close......
I think people are missing the point.
A trial start date (even an estimate) is a significant event for a company like Pharmacyte.
The CEO has a fiduciary responsibility to notify the shareholders and public of this information before presenting at a conference. Shareholders should not have to find out via a third party source.
I think the CEO should be fired by the BOD although I know this will not happen.
Still no IND date, no update on funding or diabetes. Just kick the can down the road.
As for the 4th qtr date, to me this probably means November or December at best. This CEO has never even met an estimated date. Remember, we were expected to be in trial in December 2016 and yes I know they changed to a pivitol. But that was the company's number one goal of 2016. Notice the company did not publicly issue 2017 goals.
Just disappointed but not surprised.
Even though trial date was probably an estimate it still qualifies as a significant event for the Company. That information would need to be released to the public before the event or lawsuits could follow.
Why is the CEO delaying the submission of the IND????
How are we funding the PC trial???
Are we even still working on Diabetes??????
It has been 5 months since the pre-ind meeting. It is time to communicate what the company is or is not doing or the CEO should step down NOW!!!
BIG TOBACCO STARTING TO LOOK AT MEDICAL MARIJUANA:
https://www.fool.com/investing/2017/06/16/cigarette-giant-imperial-brands-marijuana.aspx
What Imperial Brands did
Imperial Brands said earlier this week that it had named Simon Langelier as a non-executive member of its board of directors on June 12. Langelier's long history with Philip Morris gives him a pedigree that looks perfectly suited the role. In particular, the new Imperial director has worked in areas across the globe, including Latin America, Asia, and the Eastern Europe-Middle East-Africa region. He also served as president of Philip Morris' next-generation products division, which has been working on some of its highest-growth prospects.
However, what makes Langelier's appointment interesting is that he's also the chairman of a company called PharmaCielo: A Canada-based supplier of medicinal-grade cannabis oil extracts and related products. As Imperial Chairman Mark Williamson said, Langelier's "extensive international experience in tobacco and in wider consumer adjacencies will be a great asset to the board."
This PR release was extremely disappointing!!!!! Really, why bother at all.
The only item I learned from the "news" release was Dr. Lohr's travel plans.
Starting to get worried....
BioLogics:
Looks like Pharmactye is in the sweet spot relating to Biologics:
Novartis' focus on expanding its biologics-oriented staff follows the market. Transparency Market Research predicts the value of the global biologics market will more than double between 2016 and 2024, rising from $209.8 billion to $479.8 billion. Big pharma players, including Bristol-Myers Squibb, Roche and Eli Lilly, continue to invest heavily in biologics drug development, betting on delivering advances in areas from immuno-oncology to neuroscience.
That investment has been reflected in the number of novel biologics approved by the Food and Drug Administration: nearly 28% of new molecular entities approved between 2014 and 2016 were biologics.
http://www.biopharmadive.com/news/novartis-job-cuts-500-switzerland-biologics/443119/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202017-05-19%20BioPharma%20Dive%20%5Bissue:10392%5D&utm_term=BioPharma%20Dive
What happened to step g in the to do list noted by facet life?
Has step g been completed or do they not have one?? I hope facet life did not forget this step???? I hope they do not miss a step with the FDA...
Good news:
1.Facet interview brings some transparency.
2. Yuen hire.
Bad news:
1. No time frame on IND.
2. No discussion of funding IND. No partnership, license agreement, not for profit funding.
3. No news on diabetes.
4. No announced goals of company for 2017. Goals bring accountability.
Looks like a lot more time is needed, no time frame at all....and a lower stock price is on the way.
I am assuming we are doing a pivotal trial. Would an exploratory trial be faster???
I can only imagine how long it will take for Diabetes.....very scary.
There is no reason to buy this stock right now.
I own a lot of shares and I will not sell but this could get ugly and we may reach our 52 week low.
According to a post here ( I think it was your post) the company is going to issue a Q&A on why it is taking so long to file the IND. This is not good news. This tells me nothing imminent is going to happen now.
The company probably should have gone exploratory vs privotal-faster and cheaper to prove CIAB works. Now my estimate is that the company will issue the IND in July but in the meantime this stock will sink. July is crucial since their selling of stock will be prohibited due to Market Cap levels.
I believe Yuen is now running the show which is fantastic news. I believe they did not announce this to prevent panic selling. Why else would he sign on? Certainly not to be second fiddle to an inexperienced CEO.
Next to go should be Crabtree. Would like von hoff to replace but that is dreaming...
I think by now we all know that the CEO has significant shortcomings.
The biggest to me is lack of obtaining a partnership, license agreement and or not for profit funding. He can't seem to get this done.
I hope with the additions of Yuen and Makowka we get a deal done.
I am frustrated just like the other long shareholders but I do believe we will prevail in the end.
IMO Pharmacyte has been selling shares since January 2017. I would think they have more cash now than many of us think. The addition of several highly successful new members to the Pharmacyte team should allay any fears.
I do believe a lot of things are going on behind the scenes. But we are close to a point where the CEO has to let us know what he is doing or he should step down.
I would expect Pharmactye to come out with an announcement on his background today??
I did the same research as you and found his current focus is stem cells. However, Pharmacyte does not currently have a license from AustriaNova for using stem cells in CIAB.....or maybe we will soon????
maybe bionewton can help us with this stem cell info????
More form t sells for rest of week?
Maybe some news next week to coincide with the MMJ etf?????
You are 100% correct.
Pharmacyte has been selling shares daily to help fund a more expensive pivotal trial.
The company has failed to get a partner, license deal or funding from a not for profit institution for the pancreatic cancer trial. The CEO will continue to sell shares as long as he can which will "punish" early shareholders and supporters.
Unfortunately, the CEO has lost a lot of momentum in regards to the IND filing and the MMJ etf. I do not believe these two events will propel the PPS. It has almost become a moot point and will not generate enough buzz.
Only a partner, license, institution funding and very positive news on trial results will impact the PPS.
Historically, any major change takes Pharmacyte 3 to 4 months to resolve.
Two examples come to mind: 1. cGMP 2. BioLogic issue.
So if they met with the FDA on 1/17 then extrapilate from there. They are going from exploratory to Pivotal trial so it does take time. This does not bother me as they will get the "paperwork" done. However, the concern I have is the funding of a large pivotal trial.
The company has not been forthcoming on this.....
What ever happened to Dr. Sanjay Batra ?????
today (May 3, 2016) announced that it has appointed Dr. Sanjay Batra as its Senior Business Development Advisor.
Dr. Batra said, “I am very excited to be part of the PharmaCyte team at this pivotal time. The technology holds tremendous promise to help physicians and their patients in areas of significant unmet medical need. Mr. Waggoner has built a very solid organization, and I look forward to making contributions with pace and rigor to advance our product pipeline towards commercialization.”
I want to know what pace and rigor?. I must be missing something....
On a side note is the Diabetes Consortium celebrating their second year 420 anniversary with a little MMJ from Veridis?
Brian,
The question management should be addressing to shareholders is the status of funding for on-going operations and the trials.
The company needs a partner/license/not for profit funding ie JDRF etc. Constant selling of shares will bankrupt the company at this stage.
I know all longs are very frustrated...and they should be...
Very interesting article on Pharmacyte's MMJ program...very easy to understand what we are doing now.....
Here are a few tibits worth noting from the article:
Pivital trial will be soon:
Importantly, the ‘parental’ or originating cell line being used is identical to that being used by PharmaCyte for its pancreas cancer therapy, which is soon to enter a pivotal clinical trial.”
Goal to file with FDA after pancreatic cancer trial:
In our opinion, when it comes time to present a Cell-in-a-Box®/cannabinoid therapy to the FDA, substantial data supporting the parental cell line choice will already exist.”
Very viable partnering with big pharma:
Multi-billion-dollar big pharma companies such as Merck, Sanofi-Aventis, AbbVie and Bristol-Meyers Squibb hold cannabinoid-related patents and are conducting cannabinoid-related research. These companies also have broad oncology portfolios.
If they haven’t already, I would think that many of these companies will be taking notice of PharmaCyte’s cannabinoid therapy as a great potential partnering or licensing opportunity.”
Perhaps we are looking at Israel?:
“Interestingly, in contrast to the U.S., Israel has embraced medical Cannabis and is the world leader in cannabinoid research and production with over 500 companies in the sector and 120 ongoing studies and clinical trials.
Interesting reading on another MMJ fund...this one from Canada....
http://www.marketwatch.com/story/the-markets-first-marijuana-themed-etf-could-start-trading-next-week-2017-03-28
Just some background.
About a year and a half ago I emailed Pharmactye on competition from Viacyte on diabetes.
Dr Crabtree responded and told me Viacyte's treatment is external to the body-similar to a bandaid. You can only imagine side affects and issues.
Pharmactye's treatment is just superior so I would not worry about that competition.
The way I see it is that PMCB has "awarded" very favorable stock options to its key executives and consultants. This is good news as the options will only be valuable if the stock price increases.
So now it's just a matter of time for the IND.
This will not move the PPS right now but it is a significant PR.
You appear to be new here.
Please do your research. Pharmacyte has ODD and Biologic protection.
Look at prior announcements by management-should be on website.
We are ok on this. Patents have zero to do with trial start date.
Just a few things to keep in mind at the moment.
1. I believe it will take about 2 months to rewrite/document/update training materials etc for the PC trial.
2. As it appears to be a privital trial it will be more expensive. I believe Pharmacyte is now in a better position to apply for funding with various agencies as the pre ind meeting with the FDA is in hand. I would not be surprised if the FDA helps in this process. To me this will further delay the IND submission.
3. I expect the IND to be filed by June 2017. If earlier great.
4. We may receive positive action on the MJ etf in March. Followed by the April MJ company backed presentation.
5. Diabetes-to me a big black hole at this time????
A question during our "down" time.
Does anyone know if it is more or less advantageous for PMCB to use the comparable arm cancer drug 5-fluorouracil (FU) and the compound leucovorin (LV) vs. gemcitibine???
It would be interesting to find out why Dr.Von Hoff and Dr. Hidalgo initially selected gemcitibine over other treatments before the FDA meeting (as they are world experts in pancreatic cancer)......
Triple,
Do you have any idea as to the monetary size of the fund.
For instance, will it have a value of 10, 50, or say 100 million dollars. This will affect the amount of Pharmacyte stock the fund will buy.
Do you also know the average value of new smaller etf funds??
TIA
Brian,
It will be interesting to see the dollar size of this MJ etf especially with such a hot industry. Will the etf in total be worth 50 or 100 million? Who knows, only time will tell....
There is only one PR and date that matters now: When is the IND being submitted. All other PR's at this stage are meaningless.
IMO, I think we are months from submission. There appears to be much work to be done and Pharmacyte is extremely methodical (almost to the point of being anal).
My rough IND target date is June 21st.
Hope springs eternal. We may get some mileage out of the new MJ fund. Good work on this by some board members.
The problem with that statement was when it was issued on September 15, 2016. Pharmacyte should of known these issues on lets say January 15, 2016 and did not notify shareholders at that time.They do have top doctors that had to be aware of this.
The number one goal of Pharmactye in 2016 was to get it trials and it failed. I know it is not easy and the CEO had done a very good job but they have not been always upfront with us.
The recent cc was overall very positive but Pharmacyte left me feeling less than that. Concerns are funding and timing. At this juncture you have to be able to have some kind of reasonable date of filing the IND say 2nd qtr of 2017. There is too much ambiguity right now.
Also, I don't understand the posting of pictures on facebook and issuance of an outdated PR stating Pharmacyte is going head to head with gemcitibine when managment knew this had changed. This takes away credibility IMO.
All this said, I do believe strongly that the company will be successful. When? Who knows?
Excellent point and observation!!! I'd be curious if Pharmacyte has already applied for other trademarks?
Does Pharmacyte have 2017 goals?? Goals are important to stay focused.
I will have to replay cc but on the topics of diabetes and MJ it sounded like we met some headwinds.......
Short term impact on the cc was not good. I did expect an IND filing or date of filing....
I thought TD2 was going to lead Pharmacyte in the pre-IND meeting with the FDA? Is Pharmactye doing anything with EMA on Pancreatic Cancer? At this juncture of the game, just another meaningless PR IMO.
From reading today's news it seems like a lot of work still needs to be done. Not encouraging at this time. Following this stock is like going thru a chinese torture test....
My concern is that expectations maybe too high for the 7th.
Yes there will be very good news relating to the upcoming trial but people here are expecting a buy out or partnership. This stock could face a big drop in price if this does not materialize.
Pharmacyte needs to manage this very carefully. JMHO
The price of the stock will run when one of three things happen:
1. Pharmacyte submits its IND. By doing this it will signal the FDA will accept.
2. Announce start of pc trial date.
3. Expect the unexpected. Some out of the blue favorable announcement on diabetes.
IMO, I think Phamracyte is holding this down at the moment. But when it is lifted look out.....
If this does happen (and I don't think it will) then I believe the 21st century healthcare act would move Pharmacyte's treatment on anyway. JMO
Made my final purchases of the year under .14. Thank you to whomever.
Wishing all longs a Happy and Prosperous New Year!!!